Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy - Wikidata - awgldk - TriplyDB

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

http://www.wikidata.org/entity/Q24646296

about

Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis A new view of carcinogenesis and an alternative approach to cancer therapy Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism Glucose metabolism in gastric cancer: The cutting-edge Protective effects and mechanisms of sirtuins in the nervous system Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect What is good for the circulation also lessens cancer risk How does the metabolism of tumour cells differ from that of normal cells Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells The reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis Poor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: a meta-analysis.Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II.Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism.The Warburg effect is genetically determined in inherited pheochromocytomas Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2.Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism.Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells Energy metabolism in human pluripotent stem cells and their differentiated counterparts.Differential gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenic development.Potential therapeutic benefits of strategies directed to mitochondria.Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma.Free tubulin modulates mitochondrial membrane potential in cancer cells.Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival.TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.

P2860

Q24313608-DF829990-9A4B-41BF-A521-31E7734134B2 Q24650249-22ACF98A-7141-482E-AD41-890B9C3AAD4D Q26739857-7E49795F-84B4-446F-933C-7B62C3BFCEC6 Q26766098-15CD8DEB-BB41-402B-9517-8357AB8A4B4E Q26825585-A5479949-8553-427F-B8F7-D089D68FF2F2 Q26827829-875C1E73-AC21-411D-8658-81C225D49153 Q26859261-7E5C4F8D-56A8-49C9-8BB7-17E56D952018 Q27011856-6EE624AE-7A79-4351-9568-E458B8B9BB76 Q28072714-CE834540-72AA-43DB-A65A-0CD28559C317 Q28073392-FCAB4436-F0BA-47F6-B7A4-43446C2E5809 Q28076454-CE95F75A-0B70-4E73-8BB3-615F5CE9A36F Q28292014-1D901FF5-A394-4740-AF43-F03F4E6FD887 Q28477764-B5011C0E-E2DC-463C-B271-ACCA607233C5 Q28544747-CEAA9CDF-F9D2-404E-961B-E41D1B752078 Q28658683-3A4D7885-6729-4058-80D4-E86E22D238D3 Q30234765-3A8B33FD-3342-4B8C-B9BA-0366C0B396FD Q30540902-F17DD504-5BB4-4C4D-A743-F21EC0449A34 Q31120020-77F12AB2-EB11-4C52-AC89-646DF3628CB6 Q33504560-2BB61B5B-D5D4-49B0-9C3F-D095BC310F5B Q33540676-2C12CCCD-42C7-4E59-97A7-63F5ACBF0927 Q33554640-6398F2CC-6B24-4C61-88F9-F0E006964478 Q33587154-47219584-93BC-40ED-9847-27A110F37B28 Q33590969-5B1756A3-58E2-44F4-BB9B-5BFBCFB13322 Q33699410-BEE5D0D1-E6A4-49D0-A5DA-BBCFFAE803F3 Q33775931-9DD8AB30-D3EF-40AC-8E5B-D70112828EA9 Q33779169-F76D5200-51E5-4F1B-8A11-C43708803EBE Q33779972-A7DC1A03-535B-40FB-BED0-71E2AED299FD Q33880100-1E2B8B0B-765D-4450-82F5-6146147CB250 Q33882790-0980991C-642C-40D3-9C32-9DE5CCA988A8 Q33900808-EE442DD7-CF12-4EBE-A496-8F17180BB4E9 Q33934809-45CB2212-470D-4C9F-9FC7-B0F8BF1668EC Q33940583-26AE3ED6-6886-4B44-BD75-BFCF0125B8A2 Q34029401-11D8E21C-4C51-40A3-A9C3-6AE98624C8BB Q34117168-A93CD4D9-5233-45DD-8245-6A45FFFBA084 Q34179999-B555D2AF-2E32-488C-A244-6F5AD53FEAA0 Q34210845-5619CC22-621C-40DF-939D-04DBE55DD0D9 Q34440476-E4692BF5-1FF8-422C-A6A8-96FC227E9DE5 Q34447257-A099B1DA-8D5F-43AB-B78E-007B947B9ACA Q34539146-ADF0A43D-C701-4E97-B531-55875CCB4177 Q34768395-34DCDCC4-4258-4DF2-9AAD-AE411368015D

P2860

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

http://www.wikidata.org/entity/Q24646296

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@ast

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@en

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@nl

type

label

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@ast

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@en

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@nl

prefLabel

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@ast

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@en

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@nl

P1433

Q24646296-09FDC362-7706-4F6D-89A3-6F628AA123FF

P1476

Q24646296-361D91BD-342E-44CD-8A9C-888B273277D2

P2093

Q24646296-35FD747F-0AF6-4501-9FC8-6FC49FEA0EC3

Q24646296-758CEC20-F208-4803-A2B0-FD8A33B11EF0

Q24646296-FC546395-571F-45DD-9D8A-7779EFD411CD

P2860

Q24646296-04180960-3879-4B27-BCEC-6E3186C1175F

Q24646296-0B300986-BE75-4D6E-AEF3-9696C7801BCA

Q24646296-1BBE86D7-0333-471C-93AF-63B504D94CB6

Q24646296-1CFCE0C2-1824-4DBA-AC10-EB9285CB1F33

Q24646296-212AD159-1890-44A1-AAAC-38229839A655

Q24646296-215B47C2-3FC9-4A4F-9877-814E6CFF0C1F

Q24646296-2545A296-8A9D-44B6-97FD-1E1FC964AA27

Q24646296-341CF8C5-D0E4-41B3-8D38-E04C6A95D014

Q24646296-360833A0-5FD9-46DE-8062-0D18C448BCDA

Q24646296-3648DCEB-BFF0-4D76-8F42-85CE24D02254

P304

Q24646296-3068D26A-918B-459A-95BB-4A8052F83002

P31

Q24646296-A4CF295F-1562-4DD1-9AF0-7D021F555EFB

P3181

Q24646296-3B8F4ECA-2AD3-48A5-839A-942658E74CC3

P356

Q24646296-1449784D-A199-4494-B900-A2980E664CC6

P407

Q24646296-3EB866DE-93A6-4949-A13C-8FE282E9257A

P433

Q24646296-2814C141-D0F6-4B2E-A858-916463D39571

P478

Q24646296-EF57D732-6021-4F42-A1F7-D56B349508F7

P577

Q24646296-08EAFBC3-9C03-451B-8631-DB655F820F2F

P5875

Q24646296-0CBE830F-E3F1-46C6-8E73-8F42C5B90DD0

P698

Q24646296-F71B12C7-2D6A-4EE1-980E-A91DD7117FB8

P921

Q24646296-AAA396D5-2E66-4553-A4D4-271D684973C3

P932

Q24646296-8CB2E907-B067-4A16-8554-E52CB8AF5B79

P3181

P356

J.SEMCANCER.2008.11.006

P1433

Seminars in Cancer Biology

P1476

Hexokinase-2 bound to mitochon ...... l target for effective therapy

@en

P2093

Peter L Pedersen

http://www.w3.org/2001/XMLSchema#string

Saroj P Mathupala

http://www.w3.org/2001/XMLSchema#string

Young H Ko

http://www.w3.org/2001/XMLSchema#string

P2860

Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53

Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels

High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase

Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study

Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis

P304

17-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1139242

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.SEMCANCER.2008.11.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223604778

http://www.w3.org/2001/XMLSchema#string

P698

19101634

http://www.w3.org/2001/XMLSchema#string

P921

P932

2714668

http://www.w3.org/2001/XMLSchema#string